Powered by

BioInvent announces receipt of US FDA orphan designation for BI-1206 for mantle cell lymphoma

Jan 31, 2019 - Global Banking News

BioInvent International AB (BioInvent) (STO:BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, announced on Wednesday the grant by the US Food and Drug Administration (FDA) orphan designation for the company's proprietary antibody BI-1206 for the treatment of mantle cell lymphoma (MCL).

Orphan designation is intended to support companies developing treatments that target rare medical conditions and are expecte...